A clinical trial has been running since 2014 for the treatment of Long Chain Fatty Acids, this trial drug is called Triheptanoin.
Ultragenyx has now announced that this drug has been FDA approved and has been given to patients on compassionate grounds.
Dojolvi is a highly purified, pharmaceutical-grade, odd-carbon medium-chain triglyceride consisting of three 7-carbon fatty acids on a glycerol backbone created via a multi-step chemical process. It is designed to provide medium-chain, odd-carbon fatty acids as an energy source and metabolite replacement for people with LC-FAOD.
Dojolvi is indicated as a source of calories and fatty acids for the treatment of adult and pediatric patients with long-chain fatty acid oxidation disorders (LC-FAOD).
For more information please click on the download option.